Hong Kong Stock Movement: IVD MEDICAL fell 12.86%, with no news support, the sector's volatility has attracted market attention

Hong Kong Stock Movement

IVD MEDICAL, down 12.86%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Stocks with High Trading Volume in the Industry

BAIYUNSHAN PH, up 3.05%. Based on recent key news:

1. On October 30, BAIYUNSHAN PH's stock price rose after the release of its performance for the first three quarters of 2025. The company's operating income increased by 4.31% year-on-year, and net profit rose by 4.78%, indicating robust financial performance, which drove the stock price up by 4.61%. Source: Zhitong Finance

2. On October 28, BAIYUNSHAN PH's subsidiary Wanglaoji Health launched new products in Saudi Arabia, marking an important step in its global expansion. This news of international market expansion boosted investor confidence, further supporting the stock price increase. Source: Zhitong Finance

3. On October 28, Changcheng Securities gave BAIYUNSHAN PH an "overweight" rating, reflecting the market's optimistic expectations for its future growth. The positive rating from the investment bank provided support for the stock price. Source: Zhitong Finance. The overall performance of the traditional Chinese medicine industry is stable, and market confidence is strengthened.

YSB, down 2.27%. Based on recent news:

1. On October 27, YSB announced a buyback of 100,000 shares, totaling approximately HKD 980,000. Although buybacks are generally seen as positive news, the market reacted poorly, leading to a decline in the stock price.

2. On October 27, YSB confirmed the buyback of 100,000 shares, spending HKD 977,100. This move failed to boost investor confidence, and the stock price continued to decline. The market's lukewarm response to the buyback put pressure on the stock price.

SINOPHARM, up 0.67%. Based on recent news:

1. On October 27, SINOPHARM announced its performance for the first nine months of this year, with operating income of approximately CNY 431.479 billion, a year-on-year decrease of 2.47%; net profit attributable to the parent company was approximately CNY 5.307 billion, a year-on-year increase of 0.53%. This performance met market expectations, driving the stock price up.

2. On October 29, CICC released a research report, maintaining its net profit forecasts for SINOPHARM at CNY 7.475 billion and CNY 7.926 billion for 2025 and 2026, respectively, and maintained an "outperform" rating and target price of HKD 24.7, expecting an upside potential of 27.1%. The positive rating and target price enhanced market confidence.

3. On October 27, Credit Lyonnais released a report stating that the improvement in SINOPHARM's accounts receivable days and the launch of the "14th Five-Year Plan" will support the recovery of profit momentum. The current stock price level offers an attractive dividend yield and a low price-to-earnings ratio, with significant upside potential as operational efficiency continues to improve. The overall performance of the pharmaceutical industry is stable, with policy support.

Stocks with High Market Capitalization in the Industry

SH PHARMA, up 0.24%. Based on recent key news:

1. On October 28, SH PHARMA announced that its subsidiary Shanghai Pharmaceutical's bromperidol sustained-release tablets received the "Drug Registration Certificate" issued by the National Medical Products Administration, allowing the drug to be produced for the treatment of myasthenia gravis This approval may enhance the company's competitiveness in the pharmaceutical market and drive up the stock price.

2. On October 28, Shanghai Pharma's Hong Kong stock closed down 0.41%, with a trading volume of 1.582 million shares and a turnover of HKD 19.4127 million. Despite the approval of a new drug, investment banks have shown low interest in the stock, with no ratings from investment banks in the past 90 days, which may affect investor confidence.

3. On October 28, Zhitong Finance reported that bromperidol sustained-release tablets are the first of their kind approved in China. Shanghai Pharma has invested approximately RMB 16.009 million in the research and development of this drug, demonstrating the company's investment and potential in the field of innovative drugs. The pharmaceutical industry has seen frequent approvals of innovative drugs, leading to intense market competition